E

Everest Medicines Ltd
HKEX:1952

Watchlist Manager
Everest Medicines Ltd
HKEX:1952
Watchlist
Price: 46.8 HKD 0.65% Market Closed
Market Cap: 15.3B HKD
Have any thoughts about
Everest Medicines Ltd?
Write Note

Everest Medicines Ltd
Tax Provision

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Everest Medicines Ltd
Tax Provision Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Tax Provision CAGR 3Y CAGR 5Y CAGR 10Y
E
Everest Medicines Ltd
HKEX:1952
Tax Provision
ÂĄ0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Tax Provision
-ÂĄ507.6m
CAGR 3-Years
-48%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Tax Provision
-ÂĄ497k
CAGR 3-Years
85%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Tax Provision
-ÂĄ146.9m
CAGR 3-Years
-21%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Tax Provision
-ÂĄ511m
CAGR 3-Years
31%
CAGR 5-Years
-7%
CAGR 10-Years
-35%
Imeik Technology Development Co Ltd
SZSE:300896
Tax Provision
-ÂĄ300.6m
CAGR 3-Years
-63%
CAGR 5-Years
-62%
CAGR 10-Years
N/A
No Stocks Found

Everest Medicines Ltd
Glance View

Market Cap
15B HKD
Industry
Biotechnology

Everest Medicines Ltd., a biopharmaceutical company headquartered in Shanghai, is carving its niche in the competitive terrain of healthcare innovation. Founded in 2017, the company was envisioned as a bridge connecting groundbreaking global therapies with the Asian market, particularly China, where the demand for advanced medical solutions is substantial. While the international pharmaceutical landscape is often dominated by industry giants, Everest distinguishes itself through strategic collaborations and licensing agreements with several leading global biotech companies. These partnerships allow Everest to bring transformative therapies, particularly in oncology, immunology, and infectious diseases, to regions where they are most needed. The way Everest Medicines operates is not entirely unconventional but certainly strategic. By licensing late-stage clinical assets, the company bypasses the early, most risky, stages of drug development. Their revenue model hinges on successfully bringing these licensed drugs through regulatory pathways and then commercializing them across China and other Asian markets. With a focus on high-impact, high-need areas, Everest aims to address substantial gaps in healthcare provision while capitalizing on the potentially lucrative Asian pharmaceutical market. This model allows Everest to exploit its deep understanding of both international drug development and local regulatory landscapes to streamline the introduction of advanced therapies, thus positioning itself as a critical player in the regional healthcare ecosystem. This approach not only mitigates initial risks but also aligns its growth with the increasing healthcare demands and policy shifts favoring innovation in Asia.

Intrinsic Value
41.92 HKD
Overvaluation 10%
Intrinsic Value
Price
E

See Also

What is Everest Medicines Ltd's Tax Provision?
Tax Provision
0 CNY

Based on the financial report for Dec 31, 2023, Everest Medicines Ltd's Tax Provision amounts to 0 CNY.

Back to Top